Indoco Remedies Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Premier Energies Ltd, Shiva Texyarn Ltd, Waaree Energies Ltd and Khandwala Securities Ltd are among the other losers in the BSE's 'B' group today, 22 January 2025.

Indoco Remedies Ltd lost 13.90% to Rs 294.75 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 25276 shares were traded on the counter so far as against the average daily volumes of 3713 shares in the past one month.

Premier Energies Ltd tumbled 11.89% to Rs 1036.15. The stock was the second biggest loser in 'B' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 87379 shares in the past one month.

Shiva Texyarn Ltd crashed 11.75% to Rs 228. The stock was the third biggest loser in 'B' group.On the BSE, 8298 shares were traded on the counter so far as against the average daily volumes of 4251 shares in the past one month.

Waaree Energies Ltd dropped 10.32% to Rs 2397. The stock was the fourth biggest loser in 'B' group.On the BSE, 2.17 lakh shares were traded on the counter so far as against the average daily volumes of 90579 shares in the past one month.

Khandwala Securities Ltd plummeted 10.14% to Rs 28.01. The stock was the fifth biggest loser in 'B' group.On the BSE, 3530 shares were traded on the counter so far as against the average daily volumes of 5298 shares in the past one month.

Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025.

With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).

Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025.

With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).

Powered by Capital Market - Live News

Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24.

The company reported a pre-tax loss of Rs 14.35 crore in Q3 FY25 as against profit before tax of Rs 35.22 crore posted in Q3 FY24. The firm recorded exceptional items of Rs 0.99 crore in the December quarter 2025.

Total expenses fell 6.03% YoY to Rs 391.59 crore in Q3 FY25. The cost of materials consumed was at Rs 91.54 crore in Q3 FY25 (down 20.54% YoY), and employee benefit expenses stood at Rs 90.72 crore in Q3 FY25 (down 3.86% YoY) during the quarter.

EBIDTA stood at Rs 20.10 crore in the third quarter of FY25, down 69.21% from Rs 65.30 crore posted in Q3 FY24.

On a nine-month basis, the company's standalone net profit tumbled 77.85% to Rs 17.51 crore on 13.04% decrease in revenue to Rs 1,153.7 crore in 9M FY25 over 9M FY24.

Aditi Panandikar, MD, Indoco Remedies, said, “Domestic Formulation Business continued to contribute to revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.”

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).

Powered by Capital Market - Live News

Premier Energies Ltd, Shiva Texyarn Ltd, Waaree Energies Ltd and Khandwala Securities Ltd are among the other losers in the BSE's 'B' group today, 22 January 2025.

Indoco Remedies Ltd lost 13.90% to Rs 294.75 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 25276 shares were traded on the counter so far as against the average daily volumes of 3713 shares in the past one month.

Premier Energies Ltd tumbled 11.89% to Rs 1036.15. The stock was the second biggest loser in 'B' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 87379 shares in the past one month.

Shiva Texyarn Ltd crashed 11.75% to Rs 228. The stock was the third biggest loser in 'B' group.On the BSE, 8298 shares were traded on the counter so far as against the average daily volumes of 4251 shares in the past one month.

Waaree Energies Ltd dropped 10.32% to Rs 2397. The stock was the fourth biggest loser in 'B' group.On the BSE, 2.17 lakh shares were traded on the counter so far as against the average daily volumes of 90579 shares in the past one month.

Khandwala Securities Ltd plummeted 10.14% to Rs 28.01. The stock was the fifth biggest loser in 'B' group.On the BSE, 3530 shares were traded on the counter so far as against the average daily volumes of 5298 shares in the past one month.

Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025.

With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).

Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025.

With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).

Powered by Capital Market - Live News

Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24.

The company reported a pre-tax loss of Rs 14.35 crore in Q3 FY25 as against profit before tax of Rs 35.22 crore posted in Q3 FY24. The firm recorded exceptional items of Rs 0.99 crore in the December quarter 2025.

Total expenses fell 6.03% YoY to Rs 391.59 crore in Q3 FY25. The cost of materials consumed was at Rs 91.54 crore in Q3 FY25 (down 20.54% YoY), and employee benefit expenses stood at Rs 90.72 crore in Q3 FY25 (down 3.86% YoY) during the quarter.

EBIDTA stood at Rs 20.10 crore in the third quarter of FY25, down 69.21% from Rs 65.30 crore posted in Q3 FY24.

On a nine-month basis, the company's standalone net profit tumbled 77.85% to Rs 17.51 crore on 13.04% decrease in revenue to Rs 1,153.7 crore in 9M FY25 over 9M FY24.

Aditi Panandikar, MD, Indoco Remedies, said, “Domestic Formulation Business continued to contribute to revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.”

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).

Powered by Capital Market - Live News